SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the pricing of its initial public offering
TRB-061 is an investigational TNFR2 agonist with the potential to address a range of immune-mediated diseases Unblinded single- and multiple-dose results in healthy participants showed consistent pharmacokinetics and reproducible activation and expansion of immunoregulatory Tregs, supporting proof
TRB-071, a CD30 agonist antibody designed to activate and expand tissue Tregs and block the CD30L-mediated inflammatory pathway, is progressing through IND-enabling studies TRB-051, which is partnered with Lilly, is expected to advance into Phase 2a clinical development in lupus with cutaneous
Data from human atopic dermatitis (“AD”) skin identify altered tissue Treg programs and support TNFR2 as a regulator of immune homeostasis in tissue TRB-061, a novel TNFR2 agonist, induced selective Treg activity in vitro and pharmacodynamic expansion of tissue-licensed effector Tregs in non-human
By selectively augmenting regulatory T cells (“Tregs”), TRB-061 is designed to restore immune balance and promote repair in skin and other barrier tissues Sixteen-week Phase 1b data anticipated in the first half of 2027 SOUTH SAN FRANCISCO, April 29, 2026 – TRex Bio, Inc.
Proceeds support the continued clinical development of TRB-061, a novel TNFR2 agonist designed to selectively activate regulatory T cells (“Tregs”) in inflammatory diseases affecting skin and other barrier tissues, including atopic dermatitis The single ascending dose portion of the ongoing Phase
